organization · Reporting owner
SCP Vitalife Partners (Israel) II, L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lifeward Ltd.RWLK · Entity 7620 | 10% owner | June 26, 2017 | June 28, 2017 |
| Societal CDMO, Inc.REPH · Entity 92137 | 10% owner | December 22, 2020 | December 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lifeward Ltd.
Report date June 26, 2017 · Filed June 28, 2017
Jointly reported with SCP Vitalife II Associates, L.P., SCP Vitalife II GP, Ltd., CHURCHILL WINSTON J, LUDOMIRSKI ABRAHAM
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value NIS 0.01 per shareSEC Table I · non-derivative | Direct | 339,900 |
Last balance in matching sequence
After 2017-06-27 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-06-26 · Sale · Disposed 9,271 · Balance 352,411 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 15, 2016. F2: The Ordinary Shares are directly held by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife") and indirectly held by SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"), the sole general partner of SCP Vitalife, SCP Vitalife II, GP, Ltd. ("SCP Vitalife GP"), the sole general partner of SCP Vitalife Associates, and the individual directors of SCP Vitalife GP (SCP Vitalife Associates, SCP Vitalife GP and the individual directors of SCP Vitalife GP together, the "SCP Vitalife Indirect Reporting Persons"). The individual directors of SCP Vitalife GP are Jeffrey Dykan, Winston J. Churchill, Abraham Ludomirski and Wayne B. Weisman. The SCP Vitalife Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the SCP Vitalife Ordinary Shares in which the SCP Vitalife Indirect Reporting Persons have no pecuniary interest. Row 2 · 2017-06-27 · Sale · Disposed 12,511 · Balance 339,900 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 15, 2016. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.2000, inclusive. The reporting person undertakes to provide to ReWalk Robotics, Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. F2: The Ordinary Shares are directly held by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife") and indirectly held by SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"), the sole general partner of SCP Vitalife, SCP Vitalife II, GP, Ltd. ("SCP Vitalife GP"), the sole general partner of SCP Vitalife Associates, and the individual directors of SCP Vitalife GP (SCP Vitalife Associates, SCP Vitalife GP and the individual directors of SCP Vitalife GP together, the "SCP Vitalife Indirect Reporting Persons"). The individual directors of SCP Vitalife GP are Jeffrey Dykan, Winston J. Churchill, Abraham Ludomirski and Wayne B. Weisman. The SCP Vitalife Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the SCP Vitalife Ordinary Shares in which the SCP Vitalife Indirect Reporting Persons have no pecuniary interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 15, 2016.
F2: The Ordinary Shares are directly held by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife") and indirectly held by SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"), the sole general partner of SCP Vitalife, SCP Vitalife II, GP, Ltd. ("SCP Vitalife GP"), the sole general partner of SCP Vitalife Associates, and the individual directors of SCP Vitalife GP (SCP Vitalife Associates, SCP Vitalife GP and the individual directors of SCP Vitalife GP together, the "SCP Vitalife Indirect Reporting Persons"). The individual directors of SCP Vitalife GP are Jeffrey Dykan, Winston J. Churchill, Abraham Ludomirski and Wayne B. Weisman. The SCP Vitalife Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the SCP Vitalife Ordinary Shares in which the SCP Vitalife Indirect Reporting Persons have no pecuniary interest.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.2000, inclusive. The reporting person undertakes to provide to ReWalk Robotics, Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
Societal CDMO, Inc.
Report date December 22, 2020 · Filed December 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 701,017 |
Reported balance
After 2020-12-22 transaction · row 1
1 source rowRow 1 · 2020-12-22 · Sale · Disposed 18,830 · Balance 701,017 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.1001 to $3.3058, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.1001 to $3.3058, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2020 Filed Dec 28, 2020 20:18 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 18,830 | $3.17 | $59,691.10 |
DisclosureSEC source: 0001192482-20-000850 · edgar.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,017 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.1001 to $3.3058, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 19:53 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 6,208 | $3.03 | $18,812.72 |
DisclosureSEC source: 0001192482-20-000846 · edgar.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,847 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.03 to $3.035, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 16:21 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 1,579 | $8.84 | $13,955.52 |
DisclosureSEC source: 0001192482-18-000033 · edgar.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,055 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.7700 to $8.8900, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 19:45 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 6,635 | $8.73 | $57,943.46 |
DisclosureSEC source: 0001192482-18-000010 · edgar.xml · nonDerivative · entry 2 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,634 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.60 to $8.95, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 19:45 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 6,329 | $9.04 | $57,195.17 |
DisclosureSEC source: 0001192482-18-000010 · edgar.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,269 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.7500 to $9.1800, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 16:07 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 4,110 | $9.19 | $37,790.63 |
DisclosureSEC source: 0001192482-18-000002 · edgar.xml · nonDerivative · entry 2 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 740,598 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.0650 to $9.4300, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 16:07 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 1,980 | $9.44 | $18,690.21 |
DisclosureSEC source: 0001192482-18-000002 · edgar.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744,708 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.3600 to $9.5300, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| December 27, 2017 Filed Dec 28, 2017 16:21 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 2,803 | $9.54 | $26,737.26 |
DisclosureSEC source: 0001192482-17-000329 · edgar.xml · nonDerivative · entry 2 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,688 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.42 to $9.62, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 16:21 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 1,602 | $9.59 | $15,364.14 |
DisclosureSEC source: 0001192482-17-000329 · edgar.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 749,491 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.46 to $9.74, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| June 27, 2017 Filed Jun 28, 2017 20:28 UTC | Lifeward Ltd. RWLK · Entity 7620 | SaleOrdinary Shares, par value NIS 0.01 per share | 12,511 | $3.09 | $38,697.77 |
DisclosureSEC source: 0001144204-17-034636 · v469916_4.xml · nonDerivative · entry 2 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner SCP Vitalife II Associates, L.P. · CIK 0001662464 · 10% owner SCP Vitalife II GP, Ltd. · CIK 0001662461 · 10% owner CHURCHILL WINSTON J · CIK 0000923792 · 10% owner LUDOMIRSKI ABRAHAM · CIK 0001235402 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,900 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 15, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.2000, inclusive. The reporting person undertakes to provide to ReWalk Robotics, Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. F2 · ownership.direct: The Ordinary Shares are directly held by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife") and indirectly held by SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"), the sole general partner of SCP Vitalife, SCP Vitalife II, GP, Ltd. ("SCP Vitalife GP"), the sole general partner of SCP Vitalife Associates, and the individual directors of SCP Vitalife GP (SCP Vitalife Associates, SCP Vitalife GP and the individual directors of SCP Vitalife GP together, the "SCP Vitalife Indirect Reporting Persons"). The individual directors of SCP Vitalife GP are Jeffrey Dykan, Winston J. Churchill, Abraham Ludomirski and Wayne B. Weisman. The SCP Vitalife Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the SCP Vitalife Ordinary Shares in which the SCP Vitalife Indirect Reporting Persons have no pecuniary interest. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 20:28 UTC | Lifeward Ltd. RWLK · Entity 7620 | SaleOrdinary Shares, par value NIS 0.01 per share | 9,271 | $3.00 | $27,813.00 |
DisclosureSEC source: 0001144204-17-034636 · v469916_4.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner SCP Vitalife II Associates, L.P. · CIK 0001662464 · 10% owner SCP Vitalife II GP, Ltd. · CIK 0001662461 · 10% owner CHURCHILL WINSTON J · CIK 0000923792 · 10% owner LUDOMIRSKI ABRAHAM · CIK 0001235402 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,411 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 15, 2016. F2 · ownership.direct: The Ordinary Shares are directly held by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife") and indirectly held by SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"), the sole general partner of SCP Vitalife, SCP Vitalife II, GP, Ltd. ("SCP Vitalife GP"), the sole general partner of SCP Vitalife Associates, and the individual directors of SCP Vitalife GP (SCP Vitalife Associates, SCP Vitalife GP and the individual directors of SCP Vitalife GP together, the "SCP Vitalife Indirect Reporting Persons"). The individual directors of SCP Vitalife GP are Jeffrey Dykan, Winston J. Churchill, Abraham Ludomirski and Wayne B. Weisman. The SCP Vitalife Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the SCP Vitalife Ordinary Shares in which the SCP Vitalife Indirect Reporting Persons have no pecuniary interest. Read SEC document |
| March 16, 2017 Filed Mar 16, 2017 17:37 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 3,170 | $7.93 | $25,124.79 |
DisclosureSEC source: 0001123292-17-000694 · edgar.xml · nonDerivative · entry 3 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 751,093 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.84 to $8.02, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 17:37 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 6,399 | $8.01 | $51,270.07 |
DisclosureSEC source: 0001123292-17-000694 · edgar.xml · nonDerivative · entry 2 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 754,263 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.91 to $8.05, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 17:37 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 5,454 | $8.04 | $43,847.98 |
DisclosureSEC source: 0001123292-17-000694 · edgar.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,662 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.73 to $8.26, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 16:16 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 3,334 | $7.59 | $25,311.73 |
DisclosureSEC source: 0001123292-17-000452 · edgar.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,116 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.45 to $7.84, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 16:29 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 1,100 | $7.86 | $8,642.92 |
DisclosureSEC source: 0001123292-17-000445 · edgar.xml · nonDerivative · entry 3 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 769,450 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.78 to $7.93, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 16:29 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 2,164 | $7.88 | $17,052.32 |
DisclosureSEC source: 0001123292-17-000445 · edgar.xml · nonDerivative · entry 2 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770,550 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 16:29 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 766 | $7.96 | $6,094.22 |
DisclosureSEC source: 0001123292-17-000445 · edgar.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772,714 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.90 to $8.01, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 16:16 UTC | Societal CDMO, Inc. REPH · Entity 92137 | SaleCommon Stock | 2,651 | $7.97 | $21,129.53 |
DisclosureSEC source: 0001123292-17-000428 · edgar.xml · nonDerivative · entry 1 SCP Vitalife Partners (Israel) II, L.P. · CIK 0001602484 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 773,480 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.72 to $8.21, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.